## Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

#### GALE PACIFIC LIMITED

ABN

80 082 263 778

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Performance Rights

1,403,000

\* 1,783,733 performance rights which were previously issued have lapsed upon cessation of employment of the holders.

The Performance Rights are issued to Senior Executives under the Company's Performance Rights Share Plan (**Plan**). The terms of the Performance Rights are summarised below.

- 1. Each Performance Right grants a right to acquire one fully paid ordinary share in the Company subject to satisfaction of relevant performance conditions. The performance conditions are based on the Company's earnings per share and continuation of employment over a performance period of 3 years.
- 2. Performance Rights have been granted at no cost to the employees.
- 3. The date of grant of the Performance Rights is 21 September 2016.
- 4. There is no amount payable by an employee upon vesting of a Performance Right.

4

•

- 5. An unvested Performance Right will lapse upon the earliest to occur of:
  - a. the holder ceasing to be an employee of Gale Pacific Limited or a subsidiary (each Group Company) before а а Performance Right has vested by reason of his or her death, disability, bona fide redundancy or other reason approved by the Board, except to the extent to which Board determines that the such Performance Rights will be deemed to vest:
  - the holder ceasing to be an employee of a Group Company for any reason other than set out in the paragraph immediately above;
  - c. the holder attempting an unauthorised transfer of the Performance Right in accordance with Plan rules;
  - d. the holder failing to meet the performance conditions in the prescribed period; or
  - e. the expiry date of the Performance Rights, being 1 December 2019.

No. Performance Rights will not be quoted or rank equally with any class of quoted securities. However, fully paid ordinary shares issued on the vesting of the Performance Rights will be quoted. Under the terms of issue of the Performance Rights, those shares will rank:

- For any dividend with a record date (for determining entitlements to it) which is the same as or after the date of issue of the shares, equally with the fully paid ordinary shares then on issue; and
- From the date of issue of the shares, in all other respects, equally with the fully paid ordinary shares then on issue.
- 5 Issue price or consideration

Do the +securities rank equally

in all respects from the +issue

date with an existing +class of

If the additional +securities do not rank equally, please state:

the extent to which they

dividend, (in the case of a

trust, distribution) or interest

the extent to which they do

not rank equally, other than

Nil

in relation to the next dividend, distribution or interest payment

participate for the next

the date from which they do

quoted +securities?

payment

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) The Performance Rights are issued to Senior Executives under the Company's Performance Rights Share Plan as a standard component of remuneration which is intended to comprise the long term incentive component of the Senior Executives' remuneration.

<sup>+</sup> See chapter 19 for defined terms.

6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h *in relation to the* +*securities the subject of this Appendix 3B*, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of +securities issued without security holder approval under rule 7.1
- 6d Number of +securities issued with security holder approval under rule 7.1A
- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements



N/A

No

1,403,000

Nil

N/A

N/A

N/A

N/A

See Annexure 1

 7 +Issue dates Note: The issue date may be prescribed by 21 September 2016

ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Number and +class of all 8 +securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
297,474,396	Fully paid ordinary shares

- 9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)
- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Number	+Class
5,005,405	Performance Rights

Rank equally

## Part 2 - Pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates
- 15 \*Record date to determine entitlements
- Will holdings on different 16 registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions

N/A			
N/A			

N/A

N/A

N/A

N/A

N/A

<sup>+</sup> See chapter 19 for defined terms.

18 Names of countries in which the entity has security holders who will not be sent new offer documents

> Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

20 Names of any underwriters

- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?

N/A

31	How do security holders sell <i>part</i> of their entitlements through a	N/A
	broker and accept for the balance?	

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 +Issue date

N/A			

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

N/A

34 Type of +securities

(tick one)



(b)

+Securities described in Part 1

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

## Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories
 1,000
 1,001 - 5,000
 5,001 - 10,000

5,001 - 10,000 10,001 - 100,000 100,001 and over

37

A copy of any trust deed for the additional +securities

## Entities that have ticked box 34(b)

<sup>+</sup> See chapter 19 for defined terms.

- 38 Number of \*securities for which \*quotation is sought
- 39 +Class of +securities for which quotation is sought
- 40 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period


(if issued upon conversion of another +security, clearly identify that other +security)

42 Number and +class of all +securities quoted on ASX (*including* the +securities in clause 38)

N/A

N/A

n N/A



Number	+Class
N/A	N/A

#### **Quotation agreement**

- <sup>1</sup> +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the <sup>+</sup>securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

SOPHIE KARZIS Company Secretary 21 September 2016

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Add the following:				
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	Nil			
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>				
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>				
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>				
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil			
"A"	297,474,396			

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15 [Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	44,621,159
Step 3: Calculate "C", the amount of that has already been used	placement capacity under rule 7.1
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	1,403,000 performance rights issued on 21 September 2016
Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	1,403,000
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in Step 2	
Subtract "C"	1,403,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	43,218,159

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	N/A		
Step 3: Calculate "E", the amount of that has already been used	placement capacity under rule 7.1A		
<ul> <li>Insert number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> <li>"E"</li> </ul> </li> </ul>	N/A N/A N/A I to calculate remaining placement		
"A" x 0.10	N/A		
Note: number must be same as shown in Step 2			
Subtract "E"	N/A		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.10] – "E"	N/A		
	Note: this is the remaining placement capacity under rule 7.1A		

<sup>+</sup> See chapter 19 for defined terms.